All In Biotech

Drug Trial Radar · NCT03789123

Effects of Dienogest and Dienogest Plus Estradiol Valerate in Ovarian Endometrioma

Effects of Dienogest and Dienogest Plus Estradiol Valerate on Ovarian Reserve and Endometrioma Size

Last checked: Nov 20, 2026Latest source record: Dec 28, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 710 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

710

Planned (sponsor's estimate)

Start

Jan 1, 2019

Primary completion

Jul 1, 2019

Study completion Dec 1, 2019

Sponsor

Lead sponsor
Bagcilar Training and Research HospitalGovernment (non-federal)
Sponsor type
Government (non-federal)
Collaborators
Kocaeli Derince Education and Research Hospital; Suleymaniye Birth And Women's Health Education And Research Hospital
First posted
Dec 28, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 40 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Progesterone resistance in endometriosis is a known fact. The progestin derivatives used in endometriosis cause decidualization and atrophy of ectopic foci. Moreover, they inhibit neo-angiogenesis, provide suppress expansile/destructive growth facilitated by matrix metalloproteinases, and implantation of ectopic foci. The effect of drugs containing the estrogen-progesterone combination is mainly based on the inhibition of ovulation, decidualization and atrophy of ectopic foci. In estrogen-progesterone mechanism, it is known that estrogen has a progesterone receptor-enhancing effect, which may make progesterone more potent. Based on this, the investigators hypothesized that estrogen added to progesterone could lead to a further reduction in endometrioma size by various mechanisms which probably include the increased progesterone sensitivity in endometriosis. In addition, the investigators hypothesized that this therapy can alleviate the destructive effect of endometriomas on the ovarian reserve.

Conditions

  • Ovarian Reserve

Interventions

  • Estradiol valerate/dienogestDrug

    The effects of drugs given for endometrioma and contraception will be observed on ovarian reserve, endometrioma size and pain score.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Ovarian reserveTime frame: up to 24 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Tolga Karacan

    Istanbul, Bagcilar, Turkey (Türkiye) · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.